HTG Announces Availability of Fixed Arrays for Rapid Gene Expression Analysis at American Association for Cancer Research Meeting
HTG provides molecular testing capabilities for clinical researchers, pharmaceutical clinical development and clinical testing laboratories. The Company’s molecular technology solutions include multiplexed and multiparameter assays for precise, accurate, and cost-effective detection of mRNA, miRNA, siRNA, gene fusions, slice variants, and single nucleotide variants (SNVs). The platform allows scientists to test any sample, including formalin fixed paraffin embedded (FFPE) tissue samples while avoiding extraction and target amplification.
“Due to the inherent variance in samples, researchers need the confidence and predictability of a set of vetted control genes to conduct quantitative molecular analysis,” said TJ Johnson, chief executive officer, HTG Molecular Diagnostics. “HTG’s new arrays are designed to help researchers glean both meaningful and accurate results. Our goal is to provide state-of-the-art testing solutions to help our customers shorten their validation studies. In drug discovery and development as well as academic translational medicine, the qFix Arrays offer a rapid gene expression analysis platform that’s reliable and easy to use.”
About HTG Molecular Diagnostics
HTG Molecular Diagnostics is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. The Company’s qNPA™ molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. Privately-held HTG is based in Tucson, Arizona. Additional information is available at www.htgmolecular.com.